Europe Liver Cancer Therapeutics Market Size, Share, Trends and Outlook 2023-2030

Market Overview

The Europe liver cancer therapeutics size was valued at US$ 384 million in 2022 and is estimated to reach US$ 627 million by 2030, growing at a CAGR of 8.95% during the forecast period (2023-2030).

Liver cancer is a chronic, life-threatening, advanced condition that initiates in liver cells. The liver is the critical organ in the human body, found in the upper right of the abdomen underneath the right of the lungs. The liver produces enzymes and bile to digest food. It also delivers blood-clotting proteins and clarifies the blood by removing harmful materials.

Download Sample: https://www.datamintelligence.com/download-sample/europe-liver-cancer-therapeutics-market

Market Drivers: Europe's market is expanding as a result of an increase in liver cancer cases.

One in ten patients with hepatocellular carcinoma survive for five years or more, according to the European Commission, which estimates that around three-quarters of liver cancer patients in Europe have this kind of disease. Additionally, about 98,000 people in Europe get a liver cancer diagnosis each year, and around 89,000 of them pass away from the disease, according to the European Association for the Study of the Liver.
Considering that up to half of patients get a late diagnosis, this is a significant issue. Thus, the key to beating liver cancer is prevention and early diagnosis. Global Policy Reporting reports that throughout the previous 20 years, liver cancer-related mortality in Europe has increased by 70%. In 2020, about 87,000 Europeans received a liver cancer diagnosis, and 78,000 of them died away.

Market Segmentation: During the projected period (2023-2030), chemotherapy is anticipated to have a larger share of the liver cancer treatment market.

Because of the increasing emphasis on chemotherapy in research, the chemotherapy sector is expected to dominate the European liver cancer therapies market. As per a Pan European Networks Ltd article from October 2022, for example, a novel medication found at the University of Barcelona has the ability to impede enzyme development and cell proliferation, which might significantly transform the treatment of liver cancer.

Market Companies:

The key players operating in the Europe Liver Cancer Therapeutics market are Amgen Inc., AstraZeneca PLC, Bayer AG, Celgene Corporation, Eli Lilly, Bristol-Myers Squibb Company, Gilead Sciences, Inc., Takeda Pharmaceutical Company Limited, Daiichi Sankyo Company, Limited, and UCB SA. among others.

By Type

• Hepatocellular Carcinoma
• Cholangio Carcinoma
• Hepatoblastoma
• Others

By Therapy Type

• Targeted Therapy
• Radiation Therapy
• Immunotherapy
• Chemotherapy

By End User

• Hospitals And Clinics
• Ascs
• Cancer Rehabilitation Centers

By Country

• Germany
• U.K
• France
• Italy
• Spain

Geographical Share: Germany should dominate Europe's liver cancer treatments industry.

Germany will dominate the European liver cancer treatments market in the future due to rising research and liver cancer incidence. Scientists from the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) and the Hebrew University in Jerusalem found the cell of origin in mice with uncommon liver cancers called combination liver/biliary duct carcinomas in August 2022. IL-6, a pro-inflammatory immunological message, promotes carcinogenesis. Blocking IL-6 lowered mouse tumor number and size.

Related Reports:

Catecholamines Drugs Market- https://www.datamintelligence.com/research-report/catecholamines-drugs-market

Drug Discovery Outsourcing Services Market- https://www.datamintelligence.com/research-report/drug-discovery-outsourcing-services-market

Perennial Allergic Rhinitis Drugs Market- https://www.datamintelligence.com/research-report/perennial-allergic-rhinitis-drugs-market

Contact Us -
Company Name: DataM Intelligence
Email: info@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence 4Market Research is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.